Your session is about to expire
← Back to Search
Autologous HSCT for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing a new cancer treatment combining a chemotherapy drug with a new immunotherapy drug, to see if it is more effective than chemotherapy alone, and if it has fewer side effects.
- Non-Hodgkin's Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the Federal Drug Administration's thoughts on Autologous HSCT?
"Autologous HSCT is a Phase 2 clinical trial, meaning that while there is some data supporting safety, there is no existing evidence for efficacy. Our team has rated the safety at a 2."
Are there any available openings for people who want to participate in this research?
"This information is available on clinicaltrials.gov. The trial was posted on 8/16/2019 and last updated on 7/20/2022, indicating that it is actively seeking patients."
What other research studies have used Autologous HSCT?
"As of now, there are 1597 clinical trials ongoing for Autologous HSCT. 422 out of the total number of active clinical trials are in their third stage. Most trials for Autologous HSCT take place in Shanghai but there are a grand total 74423 locations running these sorts of tests worldwide."
What are some of the conditions that Autologous HSCT has been shown to help?
"Autologous HSCT is a treatment option for patients with newly diagnosed cancer as well as those who are struggling with prostate cancer, small cell lung cancer (sclc), or advanced testicular cancer."
How many people have agreed to participate in this research project?
"That is correct, the online clinical trials registry does show that this study is open for recruitment. This trial was first made public on August 16th, 2019 and was most recently updated on July 20th, 2022. The aim of the study is to enroll 47 individuals at a single site."
Are geriatric patients welcome in this clinical trial?
"This clinical trial is only for patients aged 18 to 75. If you search the database for trials with an age limit of under 18, 305 results come up. For trials with an upper age limit of over 65, 1,741 different options are available."
Might I be a good candidate for this research project?
"According to the requirements listed, patients must have a diffuse large b-cell lymphoma (dlbcl), be between 18 and 75 years old to be eligible for this trial, of which there are only 47 spots available."
Share this study with friends
Copy Link
Messenger